Cartilage Protection and Analgesic Activity of a Botanical Composition Comprised of Morus alba, Scutellaria baicalensis, and Acacia catechu

Table 3

Modified Mankin scoring system for histopathological findings for MIA-induced rats treated with UP1306, UP446, and their composition.

Group	Dose (mg/kg)	MIA mg/joint		Structural abnormality	Bone at articular surfaces	Inflammation/cellular infiltration	Fibrovascular proliferation	Matrix GAGs
Control−	0	0	10	1.15 ± 0.61^†	0.90 ± 0.58^†	0.75 ± 0.34	1.35 ± 0.63	1.36 ± 0.67^†
MIA+	0	0.8	10	2.53 ± 0.79	1.90 ± 0.70	1.30 ± 0.68	2.40 ± 1.02	2.68 ± 0.76
Diclofenac	10	0.8	10	1.23 ± 0.36	0.70 ± 0.24	0.55 ± 0.15^†	1.55 ± 0.69	1.44 ± 0.38
UP1306	400	0.8	10	1.56 ± 0.38^†	1.35 ± 0.50	0.81 ± 0.50	1.60 ± 0.83	1.85 ± 0.37
UP446	250	0.8	10	1.00 ± 0.40	1.05 ± 0.47	0.60 ± 0.20	1.75 ± 0.64	1.08 ± 0.34
Composition	650	0.8	10	1.10 ± 0.51	0.70 ± 0.60^†	0.25 ± 0.25	1.85 ± 0.71	1.15 ± 0.46

; ; . Composition: UP1306 + UP446. MIA: monoiodoacetate. Structural abnormality (0–6): cartilage thickness/thinning, frayed irregular surface/fissure loss, degeneration, ulcerative necrosis/fragmentation, and severe disorganization/chaotic appearance; bone at the articular surfaces (0–6): subchondral bone thickness/volume and density, osteoclastic activity, and subchondral bone damage; inflammation/cellular infiltration (0–6): cellular infiltration/inflammation and proliferation, hypercellular and cluster/hypocellular; fibrovascular proliferation (0–6): fibrovascular proliferation replacing periarticular/capsular/bone parts (pannus), condyle and/or tibial plateau, meniscus reduction, fusion, and adhesion; matrix GAGs (0–6): matrix GAGs reduction: radial, interterritorial to pericellular loss of staining, femoral condyle/tibial plateau-integrity, and thickness of articular cartilage.